OSOlga Сергеевна Selezneva

Olga Сергеевна Selezneva

*This is an algorithmically generated author record based on publicly available information.

Olga Сергеевна Selezneva has a total of 183 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical case of Aicardi–Goutières syndrome type 6

    by V. A. Akimova, E. E. Repa, V. A. Marymova, O. S. Selezneva, E. V. Dudnikova, E. A. Besedina, A. S. Badyan, A. V. Dyuzheva, E. V. Nesterova

    Primary immunodeficiencies are a group of heterogeneous diseases caused by genetic deficiency of one or another component of the immune system. Due to the lack of focus of doctors on primary immunodeficiencies in patients and the phenotypic heterogeneity of nosologies included in this group, a high percentage of undiagnosed cases are determined. A genetic cause is detected only in about 30% of patients, and most of them do not have an obvious family history. Aicardi–Goutieres syndrome is a rare monogenic autoimmune disease that primarily affects the brain in children and is caused by mutations in one of the 9 genes responsible for nucleic acid metabolism and is accompanied by increased expression of interferon-stimulated genes (interferonopathy type I). In particular, in Aicardi–Goutieres syndrome type 6 (AGS6, OMIM 615010), a mutation in the ADAR gene (locus 1q21.3) leads to the recognition of unedited double-stranded RNA with the initiation of an interferon synthesis reaction. The article presents a clinical case of AGS6 syndrome, OMIM 615010, diagnosed posthumously in a 12-year-old boy.

  • Open Access

    A case of Wiskott — Aldrich syndrome in an infant

    by E. V. Churyukina, E. V. Koreeva, O. S. Selezneva

    Wiskott — Aldrich syndrome (WAS) is a rare, X-linked combined disease with immunodeficiency caused by mutations in the WAS gene that encodes the WAS protein (WASp). Manifestations range from a relatively mild form of the disease (intermittent X-linked thrombocytopenia), characterized by thrombocytopenia with or without minor immunodeficiency, to a severe form with deep immunodeficiency, episodes of bleeding, the development of autoimmunity and an increased risk of malignancy. Many patients have intermediate degrees of severity. It is precisely this heterogeneity in the clinical spectrum that makes it difficult to make a primary diagnosis of WAS. The article presents a clinical case of primary immunodeficiency detected in a 2-month-old child.


  • Open Access

    Immunoglobulin replacement therapy in patients with primary immunodeficiency diseases in Russia

    by A. A. Mukhina, I. N. Abramova, Н. Б. Кузьменко, Yu. A. Rodina, T. V. Latysheva, E. A. Latysheva, A. M. Kostinova, N. I. Ilyina, A. S. Katrysheva, E. V. Sudarikova, et al.

    Заместительная терапия препаратами иммуноглобулинов у пациентов с первичными иммунодефицитами в Российской Федерации


  • Open Access

    Granulomatous skin lesion as a manifestation of primary immunodeficiency in children

    by O. S. Selezneva, A. Yu. Shcherbina

    Гранулематозное поражение кожи как проявление первичного иммунодефицитного состояния у детей

  • COVID-19 INFECTION IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES

    by N.Yu. Kan, Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology, Yu.A. Rodina, N.B. Kuzmenko, E.A. Deordieva, E.V. Deripapa, A.A. Roppelt, A.L. Khoreva, A.A. Moiseeva, V.I. Burlakov, et al.

    Облако Mail.ru - это ваше персональное надежное хранилище в интернете.


  • Open Access

    Гранулематозное поражение кожи как проявление первичного иммунодефицитного состояния у детей.

    by Olga Сергеевна Selezneva

    Первичные иммунодефицитные состояния (ПИДС) представляют собой генетически гетерогенную группу заболеваний из более 400 нозологий. Традиционно ПИДС проявляются повышенной восприимчивоcтью к различного рода инфекционным заболеваниям. Тем не менее в последние десятилетие все большее значение приобретают неинфекционные осложнения связанные с дисрегуляцией и аутоиммунными расстройствами. У пациентов с ПИДС часто встречаются кожные проявления, и являются одним из признаков, позволяющих заподозрить диагноз иммунодефицита в раннем детстве. При этом одним из наименее изученных кожных проявлений ПИДС являются гранулематозный дерматит. Данный обзор посвящен обобщению данных исследований патогенеза, методов диагностики и терапии гранулематозного дерматита у пациентов с различными ПИДС

  • Open Access

    Haematological complications of X-linked lymphoproliferative syndrome type 1 and 2

    by А. А. Роппельт, A. L. Laberko, V. I. Burlakov, N. Yu. Kan, Yu. A. Rodina, D. V. Yukhacheva, E. A. Viktorova, O. S. Selezneva, D. E. Pershin, V. A. Vedmedskaya, et al.

    X-linked lymphoproliferative syndrome type 1 (XLP1) and 2 (XLP2) are primary immunodeficiencies (PID), combined in one group because of shared abnormal response to Epstein–Barr virus (EBV) and caused by mutations in SH2D1A and XIAP genes, respectively. Hemophagocytic lymphohistiocytosis (HLH) is a frequent life-threatening complication of both diseases. We analyzed haematological complications, such as HLH and cytopenia, in 12 patients with XLP1 and 11 – with XLP2. The research was approved by Independent ethic committee and the academic board of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology (Moscow, Russia). Analyzed were patients who were treated or consulted in Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology (Moscow, Russia) since 2012 and in Russian Clinical Children's Hospital (Moscow, Russia) since 2003 to February 2020. 19 XLP1 patients from 13 families and 16 XLP2 patients from 14 families were included. For patients with haematological complications XLP diagnosis was based on the ESID criteria and genetically confirmed in 19 cases by detecting mutations in SH2D1A or XIAP gene (8 XLP1 and 11 XLP2 patients). Intracellular expression of corresponding SAP and XIAP proteins was performed by intracellular staining of SAP/XIAP in lymphocytes. Genetic analysis to detect mutations in SH2D1A and XIAP genes was performed by the Sanger sequencing method on Genetic Analyzer 3130х1 (Applied Biosystems, USA) according to the manufacturer protocol, or by the Multiplex Ligation-Dependent Probe Amplification method using SALSA MLPA Probemix P205 SH2D1A-XIAP-ITK (MRC-Holland, the Netherlands), or by the next-generation sequencing (NGS) method on NextSeq (Illumina) platform using a paired end tag (PET) sequencing method. Varying degree of cytopenia was present in 4 patients with XLP1 and 2 – with XLP2. None of XLP1 patients with cytopenia, and all XLP2 patients with cytopenia subsequently developed full HLH. Overall 8 XLP1 and 11 XLP2 patients developed HLH. HLH-associated mortality before hematopoietic stem cell transplantation (HSCT) was 75% in a group of XLP1 patients and 0% – in XLP2. HSCT was performed in 3 XLP1 patients, which was not sufficient for survival analysis and in 9 XLP2 patients, in whom overall survival was 74%. HLH is the most often haematological complication of XLP1 and XLP2. Fulminant HLH in XLP1 requires early and aggressive treatment. In XLP2 patients HLH remission can be reached on mono- or bicomponent immunosuppressive therapy which allows to reduce therapy-associated toxicity. In XLP2 patients cytopenia can precede HLH, while in XLP1 patients cytopenia is probably caused by other mechanisms. HSCT is a curative treatment for XLP1 and 2 which should be considered as soon as the diagnosis is made.

  • EPIDEMIOLOGY OF PRIMARY IMMUNODEFICIENCIES IN THE RUSSIAN FEDERATION

    by Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology, N.B. Kuzmenko, Yu.A. Rodina, A.L. Khoreva, A.A. Moiseeva, O.A. Shvets, I.V. Kondratenko, T.V. Latysheva, E.A. Latysheva, A.M. Kostinova, et al.

    Облако Mail.ru - это ваше персональное надежное хранилище в интернете.


  • CHARACTERISTICS OF PATIENTS WITH PRIMARY IMMUNODEFICIENCY STATES IN THE RUSSIAN FEDERATION: FROM BIRTH TO OLD AGE

    by Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology, N.B. Kuzmenko, Yu.A. Rodina, I.V. Kondratenko, А.а. Bologov, T.V. Latysheva, A.P. Prodeus, A.N. Pampura, N.I. Ilyina, E.A. Latysheva, et al.

    Облако Mail.Ru - это ваше персональное надежное хранилище в интернете. Все нужные файлы всегда под рукой, доступны в любой точке мира с компьютера или смартфона.